Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12614000267651
Ethics application status
Approved
Date submitted
11/03/2014
Date registered
13/03/2014
Date last updated
18/02/2015
Type of registration
Prospectively registered

Titles & IDs
Public title
Comparative assessment of the absorption of two generic formulations of doxycycline delayed release capsule against the innovator doxycycline delayed release tablet conducted under fasting conditions in healthy male and female volunteers
Scientific title
A single-dose, single-blinded, balanced, randomised, three-treatment, three-period, three-sequence pilot bioequivalence study of doxycycline delayed release capsules in a 3 way crossover comparison against the innovator doxycycline delayed release tablet conducted under fasting conditions in healthy male and female volunteers
Secondary ID [1] 284233 0
None
Universal Trial Number (UTN)
U1111-1153-5236
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pilot bioequivalence study conducted in healthy volunteers comparing three formulations of doxycycline with no health condition or problem studied.

Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, doxycycline belongs to a class of medicines called a tetracyclines that are used to treat a wide range of organisms and work by killing or stopping the growth of bacteria, which cause infections or make acne worse. 291346 0
Condition category
Condition code
Other 291709 291709 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Single dose, crossover study design whereby each participant receives the test formulation of doxcycline (1 x 90 mg (Test 1) on one occasion and 1 x 90 mg (Test 2) on one occasion) and the innovator formulation of doxycycline (1 x 75 mg ) on one occasion with each dose seperated by a one week washout period. The intervention for this trial is the test formulation of doxycycline.

Each dose will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check will be conducted to ensure the medication has been taken as directed.

No water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for the water consumed with the dose).
Participants are required not to eat for 10 hours before receiving each dose and to fast for approximately 4 hours after receiving each dose. Bathroom visits will be supervised to ensure no unauthorised water or food intake and for personal safety. Participants will be confined at the Clinical Site for 10 hours prior to dosing to ensure compliance can be monitored and for 24 hours after dosing.

Standard meals will be consumed at the Clinical Site with no additional food intake allowed. Alcohol breath testing will be performed upon each participant reporting to the Clinical Site 10 hours prior to dosing.

Pre and post study laboratory tests will be completed to assess the healthy of participants along with HIV, Hepatitis and drugs of abuse testing.
Intervention code [1] 288939 0
Treatment: Drugs
Comparator / control treatment
Single dose, crossover study design whereby each participant receives the test formulation of doxycycline (1 x 90 mg (Test 1) and 1 x 90 mg (Test 2)) on one occasion each and the innovator formulation of doxycycline (1 x 75 mg ) on one occasion with each dose seperated by a one week washout period. The comparator/control for this trial is the innovator formulation of doxycycline.
Control group
Active

Outcomes
Primary outcome [1] 291649 0
To compare the pharmacokinetic of doxycycline (as summarised by Cmax and AUC) for the three formulations. All plasma samples will be assayed for doxcycline using a fully validated LC/MS/MS method. Validation will be conducted to comply with EU and FDA guidelines. It is unlikely however that bioequivalence of the test and reference formulations will be demonstrated with twelve participants. However, data obtained in this study will provide valuable information in the design of the pivotal bioequivalence study.
Timepoint [1] 291649 0
0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours
Secondary outcome [1] 307229 0
Time to maximum peak concentration (Tmax) and the elimination half life (t1/2). Tmax will be the time where the maximum concentration occurred in the sample points. T1/2 = 0.693/Kel where kel is the terminal elimination rate constant.
Timepoint [1] 307229 0
0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours

Eligibility
Key inclusion criteria
Healthy males and non-pregnant females
Aged between 18 and 55
Non-smoker
BMI between 19 and 30
Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
Able to provide written informed consent
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches
Concomitant drug therapy of any kind excluding prescribed hormonal contraceptives
Used substances known to be strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erthyomycin, fluconazle and ketoconazole) or strong inducers of CYP enyzmes (such as barbiturates, carbamazepine, glucocortcoids, phenytoin and rifampin) within 28 days of study starts
Sensitivity to doxycycline, any tetracyclines or other antibiotic medicines, excipients of doxycycline
History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
Females who are breastfeeding or are planning to start a family within 60 days of dosing
Smoker (anyone who has smoked in the last 6 months)
History of alcohol or drug abuse or dependency
Participation in a drug study within 60 days of the start of the study or donated blood in the 60 days preceding the study.
Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All formulations will be labelled as Formulation A, B and C. The identification of each treatment will only be known to the Managing Director and the Section Head - Trials and Regulatory Affairs.

Each participant will be identified by a 3 digit screening number and a 2 digit subject number. The screening number will be issued once the participant has given written consent to participate in the study and the two digit subject number (randomisation number) after acceptance into the study.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation list will be prepared using a computer program for a balanced three-way crossover design.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Bio-equivalence
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
14/03/2014
Actual
21/03/2014
Date of last participant enrolment
Anticipated
Actual
3/04/2014
Date of last data collection
Anticipated
Actual
Sample size
Target
12
Accrual to date
Final
Recruitment outside Australia
Country [1] 5883 0
New Zealand
State/province [1] 5883 0
Otago

Funding & Sponsors
Funding source category [1] 288862 0
Commercial sector/Industry
Name [1] 288862 0
Mayne Pharma International Pty Ltd
Country [1] 288862 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Zenith Technology Corp Ltd
Address
156 Frederick St
Dunedin 9016
Country
New Zealand
Secondary sponsor category [1] 287558 0
None
Name [1] 287558 0
Address [1] 287558 0
Country [1] 287558 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 290691 0
Northern B Health & Disability Ethics Committee
Ethics committee address [1] 290691 0
Ministry of Health
1 the Terrace
PO Box 5013
Wellington 6145
Ethics committee country [1] 290691 0
New Zealand
Date submitted for ethics approval [1] 290691 0
Approval date [1] 290691 0
10/03/2014
Ethics approval number [1] 290691 0
14/NTB/22

Summary
Brief summary
The objective of this study is to evaluate the pharmacokinetics of the test 1 (new) formulation of 90 mg doxcycyline delayed release capsule and test 2 (new) formulation of 90 mg doxcycyline delayed release capsule relative to that of the reference formulation (innovator brand of 75 mg doxycycline delayed release tablet) following oral administration of a single dose of 90 or 75 mg in healthy male and female subjects under fasting conditions. This study is being conducted to determine the feasibility of a pivotal bioequivalence study.
Trial website
Trial related presentations / publications
No presentations or citations available. Final CSR provided to Sponsor Company for Registration Purposes.
Public notes

Contacts
Principal investigator
Name 46826 0
Dr Noelyn Hung
Address 46826 0
Zenith Technology Corporation Limited 156 Frederick Street (PO Box 1777) Dunedin 9016
Country 46826 0
New Zealand
Phone 46826 0
+6434779669
Fax 46826 0
Email 46826 0
[email protected]
Contact person for public queries
Name 46827 0
Mrs Linda Folland
Address 46827 0
Zenith Technology Corporation Limited 156 Frederick Street (PO Box 1777) Dunedin 9016
Country 46827 0
New Zealand
Phone 46827 0
+6434779669
Fax 46827 0
Email 46827 0
[email protected]
Contact person for scientific queries
Name 46828 0
Dr Tak Hung
Address 46828 0
Zenith Technology Corporation Limited 156 Frederick Street (PO Box 1777) Dunedin 9016
Country 46828 0
New Zealand
Phone 46828 0
+6434779669
Fax 46828 0
Email 46828 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.